MRA Advisory Group Makes New Investment in Guardant Health, Inc. (NASDAQ:GH)

MRA Advisory Group bought a new stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 15,275 shares of the company's stock, valued at approximately $651,000.

A number of other institutional investors have also recently added to or reduced their stakes in GH. NewEdge Advisors LLC increased its holdings in shares of Guardant Health by 13.5% in the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock worth $59,000 after acquiring an additional 230 shares during the period. Summit Investment Advisors Inc. boosted its position in shares of Guardant Health by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 12,346 shares of the company's stock valued at $377,000 after purchasing an additional 391 shares in the last quarter. Arizona State Retirement System raised its holdings in shares of Guardant Health by 1.1% during the fourth quarter. Arizona State Retirement System now owns 35,639 shares of the company's stock valued at $1,089,000 after acquiring an additional 403 shares during the period. Jones Financial Companies Lllp raised its holdings in shares of Guardant Health by 43.5% during the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock valued at $82,000 after acquiring an additional 817 shares during the period. Finally, Van ECK Associates Corp raised its position in Guardant Health by 47.4% during the fourth quarter. Van ECK Associates Corp now owns 2,887 shares of the company's stock valued at $88,000 after buying an additional 929 shares during the period. 92.60% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Guardant Health

In related news, CEO Amirali Talasaz sold 106,784 shares of Guardant Health stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $49.01, for a total transaction of $5,233,483.84. Following the transaction, the chief executive officer now owns 2,202,672 shares of the company's stock, valued at $107,952,954.72. This trade represents a 4.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders have sold 107,232 shares of company stock worth $5,252,559. Company insiders own 6.10% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Scotiabank reaffirmed an "outperform" rating on shares of Guardant Health in a research report on Monday, May 5th. Mizuho started coverage on shares of Guardant Health in a research report on Thursday, April 10th. They issued an "outperform" rating and a $55.00 price target on the stock. Raymond James reissued an "outperform" rating and issued a $59.00 price target (up previously from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. JPMorgan Chase & Co. lifted their price target on shares of Guardant Health from $50.00 to $55.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Finally, Canaccord Genuity Group boosted their target price on shares of Guardant Health from $60.00 to $65.00 and gave the stock a "buy" rating in a research report on Thursday, May 1st. Twenty analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Guardant Health presently has an average rating of "Buy" and an average price target of $53.29.

Guardant Health Stock Up 3.1%

NASDAQ:GH traded up $1.47 during mid-day trading on Monday, reaching $49.53. 2,926,769 shares of the company were exchanged, compared to its average volume of 2,130,739. Guardant Health, Inc. has a 12 month low of $20.14 and a 12 month high of $52.92. The company has a fifty day moving average of $43.05 and a 200 day moving average of $41.25. The stock has a market cap of $6.14 billion, a PE ratio of -13.91 and a beta of 1.37.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.08. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $203.47 million for the quarter, compared to analyst estimates of $189.91 million. During the same quarter in the prior year, the firm earned ($0.46) EPS. The company's revenue was up 20.8% on a year-over-year basis. On average, equities research analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.